JPWO2022025168A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022025168A5
JPWO2022025168A5 JP2022539552A JP2022539552A JPWO2022025168A5 JP WO2022025168 A5 JPWO2022025168 A5 JP WO2022025168A5 JP 2022539552 A JP2022539552 A JP 2022539552A JP 2022539552 A JP2022539552 A JP 2022539552A JP WO2022025168 A5 JPWO2022025168 A5 JP WO2022025168A5
Authority
JP
Japan
Prior art keywords
agent
delete
urticaria
agent according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539552A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022025168A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/028052 external-priority patent/WO2022025168A1/ja
Publication of JPWO2022025168A1 publication Critical patent/JPWO2022025168A1/ja
Publication of JPWO2022025168A5 publication Critical patent/JPWO2022025168A5/ja
Pending legal-status Critical Current

Links

JP2022539552A 2020-07-30 2021-07-29 Pending JPWO2022025168A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020129777 2020-07-30
PCT/JP2021/028052 WO2022025168A1 (ja) 2020-07-30 2021-07-29 凝固・線溶系と補体を介したマスト細胞および好塩基球の活性化の制御ならびにその医薬用途

Publications (2)

Publication Number Publication Date
JPWO2022025168A1 JPWO2022025168A1 (cg-RX-API-DMAC7.html) 2022-02-03
JPWO2022025168A5 true JPWO2022025168A5 (cg-RX-API-DMAC7.html) 2023-06-01

Family

ID=80036281

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539552A Pending JPWO2022025168A1 (cg-RX-API-DMAC7.html) 2020-07-30 2021-07-29

Country Status (2)

Country Link
JP (1) JPWO2022025168A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022025168A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4635182A (en) * 1984-07-03 1987-01-06 The United States Of America As Represented By The Secretary Of The Navy Apparatus for controlling multiple time-varying processes
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
KR20200103018A (ko) * 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도

Similar Documents

Publication Publication Date Title
Kasperkiewicz et al. Genetic identification and functional validation of FcγRIV as key molecule in autoantibody‐induced tissue injury
Hartwell et al. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Efthimiou et al. Life-threatening complications of adult-onset Still’s disease
Doores et al. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope
Brousseau et al. The number of people with sickle‐cell disease in the United States: national and state estimates
CN110168105B (zh) 用于对t细胞受体进行测序的系统和方法及其用途
Eberhard et al. Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Cho et al. Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab
Thaper et al. Molecular mimicry: An explanation for autoimmune diseases and infertility
Aliyarbayova et al. Macrophage migration inhibitory factor: its multifaceted role in inflammation and immune regulation across organ systems
Zehner et al. Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer
Xie et al. Expansion of Circulating T Follicular Helper Cells in Children with Acute Henoch‐Schönlein Purpura
Wang et al. Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗ 02: 01 complex
Woodruff et al. Dominant extrafollicular B cell responses in severe COVID-19 disease correlate with robust viral-specific antibody production but poor clinical outcomes
Henrich et al. Sirolimus reduces T cell cycling, immune checkpoint marker expression, and HIV-1 DNA in people with HIV
Gomez‐Perosanz et al. Human rhinovirus‐specific CD8 T cell responses target conserved and unusual epitopes
Xiao et al. PD-1 upregulation is associated with exhaustion of regulatory T cells and reflects immune activation in HIV-1-infected individuals
Toh et al. Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders
Youn et al. Three year post heart transplant outcomes of desensitized durable mechanical circulatory support patients
Lucreziotti et al. Perioperative myocardial infarction in noncardiac surgery: the diagnostic and prognostic role of cardiac troponins
Khanniche et al. Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment
Cao et al. All‐trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down‐regulating B7‐H6 expression via c‐Myc signaling
Faliti et al. Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
Wu et al. Plasma levels of complement factor I and C4b peptides are associated with HIV suppression
Zhang et al. Unraveling immune checkpoint inhibitor-associated cardiovascular toxicities: pathway insights, mechanisms, and emerging therapeutic targets